Lundbeck still looking for acquisitions despite positive Alzheimer's data

Pharmaceutical firm Lundbeck is still considering acquisition opportunities even though it is heading to the approval application stage for its Alzheimer’s medication.
Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH
Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH
by christopher due karlsson, translated by catherine brett

Lundbeck is still interested in acquisitions, despite the fact that the firm and its partner Otsuka Pharmaceuticals released positive phase III data for its candidate brexpiprazol on Monday. The target indication is agitation in Alzheimer’s patients, which is often demonstrated through angry outbursts.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading